English 
Japanese 
This paper presents the new method to analyze how peptidomimetics scaffold mimic the actual peptide, and PRISM’s scaffold advantage is confirmed.
Visualized and Quantitative Conformational Analysis of Peptidomimetics
ACS omega, 6(40), 26601-26612 (2021)
Category: News
PRISM BioLab raised 1.3 billion yen in Series C funding
PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today announced that it has raised a total of ¥1.3 billion in Series C funding on August 27. Read Full Press Release
Servier and PRISM BioLab enter drug discovery collaboration for a novel target
PRISM BioLab provides PepMetics® (peptide mimetic small molecules) Technology for generating Hit and Lead compounds against Servier’s novel target. Read Full Press Release
PRISM Biolab and Merck enter multi-project drug discovery collaboration
PRISM Biolab provides The PRISM Library, proprietary library of peptide mimetic small molecules for screening against Merck’s novel targets Read Full Press Release
PRISM Biolab and Boehringer Ingelheim enter multi-project drug discovery collaboration
PRISM Biolab provides The PRISM Library, proprietary library of peptide mimetic small molecules for screening against Boehringer Ingelheim’s novel targets Read Full Press Release
Notice of Our Merger
PRISM Pharma Co.,Ltd. (“Pharma”) and its wholly owned subsidiary, PRISM BioLab Co.,Ltd.(“BioLab”), have merged as of Octorber 1,2018. BioLab succeeds all Pharma’s rights and obligations. Because those two companies were operated as one by the same management, actual business will not change at all after this merger. PRISM BioLab Co., Ltd. President & CEO Dai...